CAJ | 학술논문

目的探讨在人表皮生长因子受体2(human epidermal growth factor receptor2,HER2)过表达型乳腺癌新辅助化疗中血清HER2/neu浓度的变化及其与疗效的相关性.方法采用酶联免疫法检测78例HER2过表达型局部进展期乳腺癌患者新辅助化疗前后血清HER2/neu的浓度,分析其变化与新辅助化疗疗效的相关性.结果 HER2过表达型乳腺癌患者新辅助化疗前后血清HER2/neu的浓度分别为(18.6±10.0) ng/ml,(11.6±6.1)ng/ml,前后比较差异有统计学意义(P ＜0.001).新辅助化疗前后血清HER2/neu浓度变化与化疗疗效相关(P =0.029).新辅助化疗前后血清HER2/neu浓度变化与病理完全缓解相关(P＜0.05).结论在HER2过表达型乳腺癌患者中,新辅助化疗前后血清HER2/neu浓度变化可作为预测化疗疗效的指标.
목적 탐토재인표피생장인자수체2(human epidermal growth factor receptor2,HER2)과표체형유선암신보조화료중혈청HER2/neu농도적변화급기여료효적상관성.방법 채용매련면역법검측78례HER2과표체형국부진전기유선암환자신보조화료전후혈청HER2/neu적농도,분석기변화여신보조화료료효적상관성.결과 HER2과표체형유선암환자신보조화료전후혈청HER2/neu적농도분별위(18.6±10.0) ng/ml,(11.6±6.1)ng/ml,전후비교차이유통계학의의(P ＜0.001).신보조화료전후혈청HER2/neu농도변화여화료료효상관(P =0.029).신보조화료전후혈청HER2/neu농도변화여병리완전완해상관(P＜0.05).결론 재HER2과표체형유선암환자중,신보조화료전후혈청HER2/neu농도변화가작위예측화료료효적지표.
Objective To explore the change of serum HER2/neu concentration during neoadjuvant chemotherapy for HER2-overexpressed breast cancer and its correlation with the response to the neoadjuvant chemotherapy.Methods The concentration of the serum HER2/neu in 78 cases of HER2-overexpressed advanced breast cancer treated with neoadjuvant chemotherapy were detected with enzyme-linked immunosordent assay(ELISA).The relationship between the serum HER2/neu concentration and the response of neoadjuvant chemotherapy was analyzed.Results The serum HER2/neu concentration of befor and after neoadjuvant chemotherapy was 18.6 ± 10.0ng/ml,11.6 ± 6.lng/ml respectively.The serum HER2/neu concentration decreased significantly(P ＜ 0.001).The response of neoadjuvant chemotherapy was correlated with the change of the serum HER2/neu concentration.The pathologic complete response was correlated with the serum HER2/neu concentration of prechemotherapy and the change of the serum HER2/neu concentration.Conclusion The change of serum HER2/neu concentration may serve as a marker predicting the response of neoadjuvant chemotherapy in HER2-overexpressed breast cancer.